Pomanda estimates the enterprise value of NUCLEOME THERAPEUTICS LIMITED at £190.3k based on a Turnover of £156.1k and 1.22x industry multiple (adjusted for size and gross margin).
nucleome therapeutics limitedEstimated Valuation
£0
Pomanda estimates the enterprise value of NUCLEOME THERAPEUTICS LIMITED at £0 based on an EBITDA of £-4.6m and a 4.87x industry multiple (adjusted for size and gross margin).
nucleome therapeutics limitedEstimated Valuation
£36.7m
Pomanda estimates the enterprise value of NUCLEOME THERAPEUTICS LIMITED at £36.7m based on Net Assets of £23m and 1.59x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Nucleome Therapeutics LimitedOverview
Nucleome Therapeutics Limited is a live company located in oxford, OX2 0HA with a Companies House number of 12109297. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2019, it's largest shareholder is
oxford science enterprises plc
with a 20.4% stake. Nucleome Therapeutics Limited is a young,
micro sized company, Pomanda has estimated its turnover at
£156.1k with
declining
growth in recent years.
Pomanda's financial health check has awarded Nucleome Therapeutics Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 7 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
3 Strong
1 Regular
7 Weak
Size
annual sales of £25.2k, make it smaller than the average company (£4.4m)
£25.2k - Nucleome Therapeutics Limited
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of -67%, show it is growing at a slower rate (12.6%)
-67% - Nucleome Therapeutics Limited
12.6% - Industry AVG
Production
with a gross margin of 33.8%, this company has a higher cost of product (55.3%)
33.8% - Nucleome Therapeutics Limited
55.3% - Industry AVG
Profitability
an operating margin of -38146.8% make it less profitable than the average company (-3.1%)
-38146.8% - Nucleome Therapeutics Limited
-3.1% - Industry AVG
Employees
with 34 employees, this is below the industry average (46)
34 - Nucleome Therapeutics Limited
46 - Industry AVG
Pay Structure
on an average salary of £82.1k, the company has an equivalent pay structure (£82.1k)
£82.1k - Nucleome Therapeutics Limited
£82.1k - Industry AVG
Efficiency
resulting in sales per employee of £741.4, this is less efficient (£128.2k)
£741.4 - Nucleome Therapeutics Limited
£128.2k - Industry AVG
Debtor Days
it gets paid by customers after 1810 days, this is later than average (53 days)
1810 days - Nucleome Therapeutics Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 5491 days, this is slower than average (56 days)
5491 days - Nucleome Therapeutics Limited
56 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Nucleome Therapeutics Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 1241 weeks, this is more cash available to meet short term requirements (34 weeks)
1241 weeks - Nucleome Therapeutics Limited
34 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 3%, this is a lower level of debt than the average (50.1%)
3% - Nucleome Therapeutics Limited
50.1% - Industry AVG
NUCLEOME THERAPEUTICS LIMITED financials
EXPORT
Nucleome Therapeutics Limited's latest turnover from December 2024 is £156.1 thousand and the company has net assets of £23 million. According to their latest financial statements, Nucleome Therapeutics Limited has 44 employees and maintains cash reserves of £12.3 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2024
Jul 2024
Jul 2023
Jul 2022
Jul 2021
Jul 2020
Turnover
156,054
25,206
720,773
343,501
Other Income Or Grants
Cost Of Sales
58,490
16,687
348,492
161,443
Gross Profit
97,564
8,519
372,281
182,058
Admin Expenses
4,907,539
9,623,799
5,117,802
1,888,074
1,379,987
726,489
Operating Profit
-4,809,975
-9,615,280
-5,117,802
-1,888,074
-1,007,706
-544,431
Interest Payable
Interest Receivable
288,982
304,032
239,962
1,469
3,860
2,190
Pre-Tax Profit
-4,520,993
-9,311,248
-4,877,840
-2,248,878
-1,003,846
-542,241
Tax
751,184
1,347,041
693,358
389,489
Profit After Tax
-3,769,809
-7,964,207
-4,184,482
-1,859,389
-1,003,846
-542,241
Dividends Paid
Retained Profit
-3,769,809
-7,964,207
-4,184,482
-1,859,389
-1,003,846
-542,241
Employee Costs
3,645,685
2,791,813
1,793,330
1,026,459
558,549
269,470
Number Of Employees
44
34
24
14
8
4
EBITDA*
-4,632,035
-9,269,789
-4,920,687
-1,780,799
-962,841
-523,494
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2024
Jul 2024
Jul 2023
Jul 2022
Jul 2021
Jul 2020
Tangible Assets
1,547,087
1,333,076
1,107,847
360,598
136,782
126,464
Intangible Assets
59,223
60,905
64,943
68,981
79,490
77,056
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
1,606,310
1,393,981
1,172,790
429,579
216,272
203,520
Stock & work in progress
Trade Debtors
125,000
125,000
Group Debtors
Misc Debtors
4,290,846
1,725,483
1,105,083
441,905
244,560
126,258
Cash
12,290,608
19,865,436
1,910,530
1,249,861
3,339,792
4,379,889
misc current assets
6,025,242
4,517,001
12,500,000
total current assets
22,731,696
26,232,920
15,515,613
1,691,766
3,584,352
4,506,147
total assets
24,338,006
27,626,901
16,688,403
2,121,345
3,800,624
4,709,667
Bank overdraft
Bank loan
Trade Creditors
503,421
251,045
328,356
131,853
75,250
30,027
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
809,314
580,783
297,429
194,381
70,149
20,569
total current liabilities
1,312,735
831,828
625,785
326,234
145,399
50,596
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
1,312,735
831,828
625,785
326,234
145,399
50,596
net assets
23,025,271
26,795,073
16,062,618
1,795,111
3,655,225
4,659,071
total shareholders funds
23,025,271
26,795,073
16,062,618
1,795,111
3,655,225
4,659,071
Dec 2024
Jul 2024
Jul 2023
Jul 2022
Jul 2021
Jul 2020
Operating Activities
Operating Profit
-4,809,975
-9,615,280
-5,117,802
-1,888,074
-1,007,706
-544,431
Depreciation
176,258
341,453
193,077
103,237
40,656
20,937
Amortisation
1,682
4,038
4,038
4,038
4,209
Tax
751,184
1,347,041
693,358
389,489
Stock
Debtors
3,310,763
745,400
663,178
197,345
118,302
126,258
Creditors
175,065
-77,311
196,503
56,603
45,223
30,027
Accruals and Deferred Income
511,885
283,354
103,048
124,232
49,580
20,569
Deferred Taxes & Provisions
Cash flow from operations
-6,504,664
-8,462,105
-4,590,956
-1,407,820
-986,340
-599,156
Investing Activities
capital expenditure
-611,460
-566,682
-940,326
-320,582
-57,617
-224,457
Change in Investments
cash flow from investments
-611,460
-566,682
-940,326
-320,582
-57,617
-224,457
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
10,732,462
18,696,662
18,451,989
-725
5,201,312
interest
288,982
304,032
239,962
1,469
3,860
2,190
cash flow from financing
11,021,444
19,000,694
18,691,951
744
3,860
5,203,502
cash and cash equivalents
cash
10,380,078
17,954,906
660,669
-2,089,931
-1,040,097
4,379,889
overdraft
change in cash
10,380,078
17,954,906
660,669
-2,089,931
-1,040,097
4,379,889
nucleome therapeutics limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for nucleome therapeutics limited. Get real-time insights into nucleome therapeutics limited's credit score, group structure and payment trends.
Perform a competitor analysis for nucleome therapeutics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in OX2 area or any other competitors across 12 key performance metrics.
nucleome therapeutics limited Ownership
NUCLEOME THERAPEUTICS LIMITED group structure
Nucleome Therapeutics Limited has no subsidiary companies.
Ultimate parent company
NUCLEOME THERAPEUTICS LIMITED
12109297
NUCLEOME THERAPEUTICS LIMITED Shareholders
The largest shareholders in Nucleome Therapeutics Limited include Oxford Science Enterprises Plc and James Davies.
oxford science enterprises plc
20.4%
james davies
15.74%
james raymond hughes
12.88%
danut jeziorska
9.64%
master & scholars of the university of oxford the chancellor
9.19%
merck ventures b.v.
7.15%
british patient capital limited
7.15%
pfizer ventures (us) llc
7.15%
johnson & johnson innovation-jjdc inc.
7.15%
danuta jeziorska
1.83%
nucleome therapeutics limited directors
Nucleome Therapeutics Limited currently has 10 directors.
The longest serving directors include
Mr James Hughes (Jul 2019) and
Dr Danuta Jeziorska (Aug 2019).
72110 - Research and experimental development on biotechnology
incorporation date
July 2019
age
6
incorporated
UK
ultimate parent company
None
accounts
Small Company
last accounts submitted
December 2024
previous names
N/A
accountant
-
auditor
RSM UK AUDIT LLP
address
nucleome therapeutics limited, i, botley road, oxford, OX2 0HA
Bank
-
Legal Advisor
-
nucleome therapeutics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to nucleome therapeutics limited.
nucleome therapeutics limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NUCLEOME THERAPEUTICS LIMITED. This can take several minutes, an email will notify you when this has completed.
nucleome therapeutics limitedCompanies House Filings - See Documents
